Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Non-cash Items (2022 - 2025)

Historic Non-cash Items for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $4.5 million.

  • Phathom Pharmaceuticals' Non-cash Items fell 9128.67% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year decrease of 9128.67%. This contributed to the annual value of $2.9 million for FY2024, which is 8101.38% down from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Non-cash Items of $4.5 million as of Q3 2025, which was down 9128.67% from $25.3 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' Non-cash Items' 5-year high stood at $51.6 million during Q3 2024, with a 5-year trough of $1.7 million in Q1 2022.
  • Its 4-year average for Non-cash Items is $19.4 million, with a median of $15.3 million in 2023.
  • The largest annual percentage gain for Phathom Pharmaceuticals' Non-cash Items in the last 5 years was 212259.56% (2023), contrasted with its biggest fall of 9281.46% (2023).
  • Quarter analysis of 4 years shows Phathom Pharmaceuticals' Non-cash Items stood at $4.5 million in 2022, then soared by 241.82% to $15.3 million in 2023, then crashed by 81.01% to $2.9 million in 2024, then surged by 54.79% to $4.5 million in 2025.
  • Its Non-cash Items was $4.5 million in Q3 2025, compared to $25.3 million in Q2 2025 and $17.1 million in Q1 2025.